PF-Atlas › Clinical Trials › NCT05722964
Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis
SHR-1906 · Phase 2
Registry ID
NCT05722964
Phase
Phase 2
Status
Completed
Drug / intervention
SHR-1906
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Start
2023-03-29
Enrollment
30
Locations
1
About this trial
To evaluate the efficacy and safety of intravenous SHR-1906 in the treatment of idiopathic pulmonary fibrosis. The study is divided into four stages: screening period, baseline period, treatment period and safe follow-up period. It is planned that 108 patients will be randomly assigned to the following three treatment groups for treatment
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05722964 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.